CTXR - Citius Pharmaceuticals, Inc.

QQQ $ 479.33 $ 3.67 (0.77 %)

DIA $ 408.48 $ 1.05 (0.26 %)

SPY $ 558.06 $ 3.17 (0.57 %)

TLT $ 97.93 $ -0.01 (-0.01 %)

GLD $ 231.49 $ 1.29 (0.56 %)

Previous Close

$ 0.6031

Open

$ 0.60

Bid

$ 0.63 x 300

Ask

$ 2.70 x 100

Day's Range

$ 0.60 - $ 0.65

52 Week Range

$ 0.48 - $ 1.07

Volume

1,146,976

Average Volume

Market Cap

Beta (5Y Monthly)

$ 0.69

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2024	06-30-2024	10-Q
2	05-14-2024	03-31-2024	10-Q
3	02-14-2024	12-31-2023	10-Q
4	12-29-2023	09-30-2023	10-K
5	08-14-2023	06-30-2023	10-Q
6	05-12-2023	03-31-2023	10-Q
7	02-10-2023	12-31-2022	10-Q
8	12-22-2022	09-30-2022	10-K
9	08-11-2022	06-30-2022	10-Q
10	05-12-2022	03-31-2022	10-Q
11	02-10-2022	12-31-2021	10-Q
12	12-15-2021	09-30-2021	10-K
13	08-12-2021	06-30-2021	10-Q
14	05-13-2021	03-31-2021	10-Q
15	02-11-2021	12-31-2020	10-Q
16	12-16-2020	09-30-2020	10-K
17	08-14-2020	06-30-2020	10-Q
18	05-14-2020	03-31-2020	10-Q
19	02-13-2020	12-31-2019	10-Q
20	12-16-2019	09-30-2019	10-K
21	08-14-2019	06-30-2019	10-Q
22	05-15-2019	03-31-2019	10-Q
23	02-14-2019	12-31-2018	10-Q
24	12-11-2018	09-30-2018	10-K
25	08-14-2018	06-30-2018	10-Q
26	05-11-2018	03-31-2018	10-Q
27	02-14-2018	12-31-2017	10-Q
28	12-13-2017	09-30-2017	10-K
29	08-14-2017	06-30-2017	10-Q
30	05-15-2017	03-31-2017	10-Q
31	02-14-2017	12-31-2016	10-Q
32	12-23-2016	09-30-2016	10-K
33	08-15-2016	06-30-2016	10-Q
34	05-20-2016	03-31-2016	10-Q
35	02-12-2016	12-31-2015	10-Q
36	12-14-2015	09-30-2015	10-K
37	08-13-2015	06-30-2015	10-Q
38	05-13-2015	03-31-2015	10-Q
39	02-17-2015	12-31-2014	10-Q
40	08-14-2014	06-30-2014	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

EF Hutton Maintains Buy on Citius Pharma, ...
08/19/2024 11:09:39

EF Hutton analyst Jason Kolbert maintains Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $6 price target.

Citius Pharma Q3 2024 GAAP EPS $(0.06) Mis...
08/12/2024 21:41:58

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.0...

penny-stock-citius-pharmaceuticals-secures-its-first-fda-approval-for-skin-cancer-drug-a-year-after-fda-rejection

Penny Stock Citius Pharmaceuticals Secures...
08/08/2024 21:41:43

Citius Pharmaceuticals receives FDA approval for Lymphir, the first therapy targeting the IL-2 receptor in relapsed or refracto...

EF Hutton Maintains Buy on Citius Pharma, ...
08/08/2024 16:59:13

EF Hutton analyst Jason Kolbert maintains Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $6 price target.

FDA Approves Citius Pharmaceuticals' Lymph...
08/08/2024 11:50:27

Citius Pharmaceuticals Announces TenX Kean...
08/05/2024 12:06:13

Citius Pharmaceuticals to receive 65.6 million shares of TenX Keane, which will be renamed Citius Oncology, Inc.Citius Pharmace...

EF Hutton Initiates Coverage On Citius Pha...
07/15/2024 13:44:33

EF Hutton analyst Jason Kolbert initiates coverage on Citius Pharma (NASDAQ:CTXR) with a Buy rating and announces Price Targ...

Citius Pharmaceuticals Reports Expected Mi...
07/10/2024 13:11:12

Multiple catalysts for potentially transformative assets in second half of 2024Strong momentum expected from positive topline r...

HC Wainwright & Co. Reiterates Buy on Citi...
05/31/2024 17:06:33

HC Wainwright & Co. analyst Vernon Bernardino reiterates Citius Pharma (NASDAQ:CTXR) with a Buy and maintains $4 price t...

Citius Pharmaceuticals To Host Investor Ca...
05/29/2024 12:47:32

Management call scheduled for Monday, June 3, 2024 at 8:30 AM ETCRANFORD, N.J., May 29, 2024 /PRNewswire/ -- Citius Pharmaceuti...

citius-pharmas-antibiotic-lock-effective-in-patients-with-catheter-associated-bloodstream-infections

Citius Pharma's 'Antibiotic Lock' Effectiv...
05/21/2024 17:40:17

Citius Pharmaceuticals' Phase 3 trial results for Mino-Lok, an antibiotic lock solution for central line-associated infecti...

12-health-care-stocks-moving-in-tuesdays-pre-market-session

12 Health Care Stocks Moving In Tuesday's ...
05/21/2024 12:06:31

Trading Halt: Halt status updated at 7:25:...
05/21/2024 11:25:06

Citius Pharmaceuticals' Phase 3 Trial Of M...
05/21/2024 11:16:39

Trading Halt: Halted at 6:55:00 a.m. ET - ...
05/21/2024 10:55:04

Citius Pharma Q1 2024 GAAP EPS $(0.06) Mis...
05/14/2024 20:25:34

Citius Pharma (NASDAQ:CTXR) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $0.13...

Citius Pharmaceuticals Announces $15M Regi...
04/26/2024 12:01:44

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
04/18/2024 12:09:32

University Of Minnesota Masonic Cancer Cen...
04/11/2024 12:40:47

National Cancer Institute (NCI)-designated research and treatment center City of Hope, in Duarte, CA, to participate in the Uni...

$citius-pharmaceuticals-announces-fda-acceptance-of-bla-resubmission-of-lymphir-for-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma$

Citius Pharmaceuticals Announces FDA Accep...
03/18/2024 12:37:38

FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of August 13, 2024